Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BC Combo THDB0207 vs Lantus and Humalog in T1D
NCT05373199Phase 1Completed
- Sponsor
- Adocia
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glargine and insulin lispro in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Adocia. Primary endpoints: Area Under the Glucose Infusion Rate Curve 0-6h and Area Under the Glucose Infusion Rate Curve 6-24h. Started May 2022; status: completed.
02
Drugs
insulin glargineinsulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05373199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373199.